Bisacodyl: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
Adeel Jamil (talk | contribs)
nocaptcha, Administrators
2,544 edits
No edit summary
Adeel Jamil (talk | contribs)
nocaptcha, Administrators
2,544 edits
No edit summary
Line 1: Line 1:
{{DrugProjectFormSinglePage
{{DrugProjectFormSinglePage
|authorTag=<!--Overview-->
|authorTag={{AJ}}
|genericName=bisacodyl
|aOrAn=a
|aOrAn=a
|drugClass=
|drugClass=laxatives
|indicationType=
|indicationType=treatment
|indication=
|indication=constipation
|hasBlackBoxWarning=Yes
|adverseReactions=nausea and vomiting.
|adverseReactions=<!--Black Box Warning-->
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
Line 15: Line 15:


<!--FDA-Labeled Indications and Dosage (Adult)-->
<!--FDA-Labeled Indications and Dosage (Adult)-->
|fdaLIADAdult======Condition1=====
|fdaLIADAdult=for temporary relief of occasional constipation and irregularity
this product generally produces a bowel movement in 6 to 12 hours


* Dosing Information
=====Dosing Information=====


:* Dosage
take with a glass of water


=====Condition2=====
table


* Dosing Information


:* Dosage
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
=====Condition3=====
 
* Dosing Information
 
:* Dosage
 
=====Condition4=====
 
* Dosing Information
 
:* Dosage
 
<!--Off-Label Use and Dosage (Adult)-->
 
<!--Guideline-Supported Use (Adult)-->
|offLabelAdultGuideSupport======Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.


<!--Non–Guideline-Supported Use (Adult)-->
<!--Non–Guideline-Supported Use (Adult)-->
|offLabelAdultNoGuideSupport======Condition1=====
|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.


<!--Pediatric Indications and Dosage-->
<!--Pediatric Indications and Dosage-->


<!--FDA-Labeled Indications and Dosage (Pediatric)-->
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
|fdaLIADPed======Condition1=====
|fdaLIADPed=There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.


<!--Off-Label Use and Dosage (Pediatric)-->
<!--Off-Label Use and Dosage (Pediatric)-->


<!--Guideline-Supported Use (Pediatric)-->
<!--Guideline-Supported Use (Pediatric)-->
|offLabelPedGuideSupport======Condition1=====
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.


<!--Non–Guideline-Supported Use (Pediatric)-->
<!--Non–Guideline-Supported Use (Pediatric)-->
|offLabelPedNoGuideSupport======Condition1=====
|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.


<!--Contraindications-->
<!--Contraindications-->
|contraindications=* Condition1
|warnings=Do not use
 
if you cannot swallow without chewing.
<!--Warnings-->
|warnings=* Description
 
====Precautions====


* Description
Ask a doctor before use if you have
stomach pain, nausea, or vomiting
a sudden change in bowel habits that lasts more than 2 weeks
When using this product
do not chew or crush tablet(s)
do not use within 1 hour after taking an antacid or milk
it may cause stomach discomfort, faintness and cramps
Stop use and ask a doctor if
you have rectal bleeding or no bowel movement after using this product. These could be signs of a serious condition.
you need to use a laxative for more than 1 week
If pregnant or breast-feeding,


<!--Adverse Reactions-->
If pregnant or breast-feeding,
ask a health professional before use.


<!--Clinical Trials Experience-->
Keep out of reach of children.
In case of overdose, get medical help or contact a Poison Control Center right away.
|clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
|clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.


Line 193: Line 132:
<!--Postmarketing Experience-->
<!--Postmarketing Experience-->
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
=====Body as a Whole=====
=====Cardiovascular=====
=====Digestive=====
=====Endocrine=====
=====Hematologic and Lymphatic=====
=====Metabolic and Nutritional=====
=====Musculoskeletal=====
=====Neurologic=====
=====Respiratory=====
=====Skin and Hypersensitivy Reactions=====
=====Special Senses=====
=====Urogenital=====
=====Miscellaneous=====
<!--Drug Interactions-->
|drugInteractions=* Drug
:* Description
<!--Use in Specific Populations-->
|FDAPregCat=
|useInPregnancyFDA=* '''Pregnancy Category'''
|useInPregnancyFDA=* '''Pregnancy Category'''
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
Line 270: Line 150:
|administration=* Oral
|administration=* Oral


* Intravenous
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.


* Description


<!--IV Compatibility-->
<!--IV Compatibility-->
Line 279: Line 157:


<!--Overdosage-->
<!--Overdosage-->
|overdose====Acute Overdose===
|overdose=There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.


====Signs and Symptoms====
<!--Pharmacology-->


* Description
<!--Drug box 2-->
 
|drugBox={{Drugbox2
====Management====
| Watchedfields = changed
| verifiedrevid = 414908012
| IUPAC_name = (pyridin-2-ylmethanediyl)dibenzene-4,1-diyl diacetate<!--generated by ACD/Name--> <br /> OR <br /> 4,4'-(pyridin-2-ylmethylene)bis(4,1-phenylene) diacetate
| image = Bisacodyl skeletal.png
| image2 = Bisacodyl ball-and-stick.png


* Description
<!--Clinical data-->
| tradename =
| Drugs.com = {{drugs.com|monograph|bisacodyl}}
| MedlinePlus = a601027
| pregnancy_category = C
| legal_status = OTC
| routes_of_administration = Oral, rectal


===Chronic Overdose===
<!--Pharmacokinetic data-->
| bioavailability = 15%
| metabolism = Hepatic ([[CYP450]]-mediated)
| elimination_half-life = 16 Hours
| excretion = primarily in the feces, systemically absorbed drug is excreted in the urine


There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
<!--Identifiers-->
 
| CASNo_Ref = {{cascite|correct|CAS}}
<!--Pharmacology-->
| CAS_number_Ref = {{cascite|correct|??}}
 
| CAS_number = 603-50-9
<!--Drug box 2-->
| ATC_prefix = A06
|drugBox=<!--Mechanism of Action-->
| ATC_suffix = AB02
|mechAction=*
| ATC_supplemental = {{ATC|A06|AG02}}
| PubChem = 2391
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2299
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 10X0709Y6I
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00245
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 942


<!--Chemical data-->
| C=22 | H=19 | N=1 | O=4
| molecular_weight = 361.391 g/mol
| smiles = O=C(Oc1ccc(cc1)C(c2ccc(OC(=O)C)cc2)c3ncccc3)C
| InChI = 1/C22H19NO4/c1-15(24)26-19-10-6-17(7-11-19)22(21-5-3-4-14-23-21)18-8-12-20(13-9-18)27-16(2)25/h3-14,22H,1-2H3
| InChIKey = KHOITXIGCFIULA-UHFFFAOYAS
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C22H19NO4/c1-15(24)26-19-10-6-17(7-11-19)22(21-5-3-4-14-23-21)18-8-12-20(13-9-18)27-16(2)25/h3-14,22H,1-2H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = KHOITXIGCFIULA-UHFFFAOYSA-N
}}
|mechAction=Bisacodyl works by stimulating enteric nerves to cause colonic mass movements (contractions). It is also a contact laxative; it increases fluid and NaCl secretion. Action of bisacodyl on small intestine is negligible; stimulant laxatives mainly promote evacuation of the colon
<!--Structure-->
<!--Structure-->
|structure=*  
|structure=*  
Line 317: Line 231:


<!--How Supplied-->
<!--How Supplied-->
|howSupplied=*
|storage=store between 20º-25ºC (68º-77ºF)
|storage=
 
|packLabel=
|packLabel=Compare to the active ingredient in Dulcolax®*
<!--Patient Counseling Information-->
 
Laxative
 
Bisacodyl
 
Stimulant laxative for gentle, dependable overnight relief
Comfort Coated TABLETS 5 mg Each
 
*This product is not manufactured or distributed by Boehringer Ingelheim Pharmaceuticals, Inc., distributor of Dulcolax® Laxative.
 
PROUDLY DISTRIBUTED BY:
 
VALU MERCHANDISERS, CO.
 
5000 KANSAS AVE
 
KANSAS CITY, KS 66106
 
TAMPER EVIDENT: DO NOT USE IF CARTON IS OPENED OR IF BLISTER UNIT IS TORN, BROKEN OR SHOWS ANY SIGNS OF TAMPERING.
 
KEEP OUTER CARTON FOR COMPLETE WARNINGS AND PRODUCT INFORMATION.
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.


Line 327: Line 261:


<!--Brand Names-->
<!--Brand Names-->
|brandNames=* ®<ref>{{Cite web | title =  | url =  }}</ref>
<!--Look-Alike Drug Names-->
|lookAlike=* A® — B®<ref name="www.ismp.org">{{Cite web  | last =  | first =  | title = http://www.ismp.org | url = http://www.ismp.org | publisher =  | date =  }}</ref>
<!--Drug Shortage Status-->
|drugShortage=
|drugShortage=
}}
}}

Revision as of 13:23, 29 December 2014

Bisacodyl
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Adeel Jamil, M.D. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Bisacodyl is a laxatives that is FDA approved for the treatment of constipation. Common adverse reactions include nausea and vomiting..

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

for temporary relief of occasional constipation and irregularity this product generally produces a bowel movement in 6 to 12 hours

Dosing Information

take with a glass of water

table

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Bisacodyl in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Bisacodyl in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding FDA-Labeled Use of Bisacodyl in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Bisacodyl in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Bisacodyl in pediatric patients.

Contraindications

There is limited information regarding Bisacodyl Contraindications in the drug label.

Warnings

Do not use 

if you cannot swallow without chewing.

Ask a doctor before use if you have stomach pain, nausea, or vomiting a sudden change in bowel habits that lasts more than 2 weeks When using this product do not chew or crush tablet(s) do not use within 1 hour after taking an antacid or milk it may cause stomach discomfort, faintness and cramps Stop use and ask a doctor if you have rectal bleeding or no bowel movement after using this product. These could be signs of a serious condition. you need to use a laxative for more than 1 week If pregnant or breast-feeding,

If pregnant or breast-feeding, ask a health professional before use.

Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Bisacodyl in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Bisacodyl in the drug label.

Drug Interactions

There is limited information regarding Bisacodyl Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

  • Pregnancy Category


Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Bisacodyl in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Bisacodyl during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Bisacodyl with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Bisacodyl with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Bisacodyl with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Bisacodyl with respect to specific gender populations.

Race

There is no FDA guidance on the use of Bisacodyl with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Bisacodyl in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Bisacodyl in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Bisacodyl in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Bisacodyl in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Oral

Monitoring

There is limited information regarding Monitoring of Bisacodyl in the drug label.

IV Compatibility

There is limited information regarding IV Compatibility of Bisacodyl in the drug label.

Overdosage

There is limited information regarding Chronic Overdose of Bisacodyl in the drug label.

Pharmacology

Template:Px
Template:Px
Bisacodyl
Systematic (IUPAC) name
(pyridin-2-ylmethanediyl)dibenzene-4,1-diyl diacetate
OR
4,4'-(pyridin-2-ylmethylene)bis(4,1-phenylene) diacetate
Identifiers
CAS number 603-50-9
ATC code A06AB02 A06AG02 (WHO)
PubChem 2391
Chemical data
Formula Template:OrganicBox atomTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox 
Mol. mass 361.391 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability 15%
Metabolism Hepatic (CYP450-mediated)
Half life 16 Hours
Excretion primarily in the feces, systemically absorbed drug is excreted in the urine
Therapeutic considerations
Pregnancy cat.

C

Legal status

OTC

Routes Oral, rectal

Mechanism of Action

Bisacodyl works by stimulating enteric nerves to cause colonic mass movements (contractions). It is also a contact laxative; it increases fluid and NaCl secretion. Action of bisacodyl on small intestine is negligible; stimulant laxatives mainly promote evacuation of the colon

Structure

File:Bisacodyl01.png
This image is provided by the National Library of Medicine.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Bisacodyl in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Bisacodyl in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Bisacodyl in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Bisacodyl in the drug label.

How Supplied

There is limited information regarding Bisacodyl How Supplied in the drug label.

Storage

store between 20º-25ºC (68º-77ºF)

Images

Drug Images

{{#ask: Page Name::Bisacodyl |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

Compare to the active ingredient in Dulcolax®*

Laxative

Bisacodyl

Stimulant laxative for gentle, dependable overnight relief Comfort Coated TABLETS 5 mg Each

  • This product is not manufactured or distributed by Boehringer Ingelheim Pharmaceuticals, Inc., distributor of Dulcolax® Laxative.

PROUDLY DISTRIBUTED BY:

VALU MERCHANDISERS, CO.

5000 KANSAS AVE

KANSAS CITY, KS 66106

TAMPER EVIDENT: DO NOT USE IF CARTON IS OPENED OR IF BLISTER UNIT IS TORN, BROKEN OR SHOWS ANY SIGNS OF TAMPERING.

KEEP OUTER CARTON FOR COMPLETE WARNINGS AND PRODUCT INFORMATION. {{#ask: Label Page::Bisacodyl |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Bisacodyl in the drug label.

Precautions with Alcohol

  • Alcohol-Bisacodyl interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

There is limited information regarding Bisacodyl Brand Names in the drug label.

Look-Alike Drug Names

There is limited information regarding Bisacodyl Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

{{#subobject: 

 |Page Name=Bisacodyl
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}}
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject: 

 |Label Page=Bisacodyl
 |Label Name=Bisacodyl11.png

}}

{{#subobject: 

 |Label Page=Bisacodyl
 |Label Name=Bisacodyl11.png

}}

Retrieved from "https://www.wikidoc.org/index.php?title=Bisacodyl&oldid=1051004"